Moreover, no steric clashes with Arg2032 (MT ROS-1) were observed (Figure 6 and Figure S3) as already reported in the literature, thereby explaining the effectivity of lorlatinib in inhibiting crizotinib-resistant NSCLC tumors. This evidence concerns the gene ROS1 and non-small cell lung carcinoma.